PCV15

BIOLOGICAL6 trials

Conditions

Heart Transplant Infection PreventionPneumococcal CarriagePneumococcal DiseasePneumococcal InfectionPneumonia, Pneumococcal

Phase 1

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

CompletedNCT05489328

PfizerPneumococcal Disease

Start: 2022-08-15End: 2022-10-07Updated: 2024-04-18

Phase 3

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

CompletedNCT05393037

Merck Sharp & Dohme LLCPneumococcal Disease

Start: 2022-07-13End: 2024-01-25Updated: 2026-02-05

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

CompletedNCT05420961

Merck Sharp & Dohme LLCPneumonia, Pneumococcal

Start: 2022-07-12End: 2023-05-16Updated: 2024-10-26

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

CompletedNCT05696080

Merck Sharp & Dohme LLCPneumococcal Infection

Start: 2023-02-13End: 2024-02-16Updated: 2026-03-03

Phase 4

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15

RecruitingNCT06731374

University of OxfordPneumococcal Carriage, Pneumococcal Disease

Start: 2025-02-24End: 2026-12-31Target: 106Updated: 2025-04-15

Unknown Phase

MISP 60528 Pneumococcal Vaccination

TerminatedNCT04845945

Montefiore Medical CenterHeart Transplant Infection Prevention

Start: 2021-06-10End: 2024-08-24Updated: 2026-02-04

Related Papers

Protocol for a phase IV, Experimental Human Pneumococcal Challenge (EHPC) model to investigate <i>Streptococcus pneumoniae</i> serotype 3 (SPN3) colonisation following PCV15, a double-blind randomised controlled trial in healthy participants aged 18-50 years in the UK (RATIONALE-15).

2025-11-24

A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8.

2025-11-10

Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial.

2025-09-12

P-45. A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Investigational Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age with Increased Risk for Pneumococcal Disease

Open Forum Infectious Diseases2025-01-29

A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine–Experienced Adults 50 Years of Age or Older (STRIDE-6)

Clinical Infectious Diseases2024-07-3125 citations